Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients

详细信息    查看全文

• 作者：Nobunori Takahashi ; Toshihisa Kojima ; Kenya Terabe ; Atsushi Kaneko…
• 关键词：Abatacept ; Concomitant methotrexate ; Japanese patients ; Prior biologics ; Rheumatoid arthritis
• 刊名：Modern Rheumatology
• 出版年：2013
• 出版时间：September 2013
• 年：2013
• 卷：23
• 期：5
• 页码：904-912
• 全文大小：381KB
• 参考文献：1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358(9285):903-1. CrossRef
  2. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344(12):907-6. CrossRef
  3. Goronzy JJ, Weyand CM. T-cell regulation in rheumatoid arthritis. Curr Opin Rheumatol. 2004;16(3):212-. CrossRef
  4. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol. 1996;14:233-8. CrossRef
  5. Silver PB, Hathcock KS, Chan CC, Wiggert B, Caspi RR. Blockade of costimulation through B7/CD28 inhibits experimental autoimmune uveoretinitis, but does not induce long-term tolerance. J Immunol. 2000;165(9):5041-.
  6. Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol. 2002;13(2):559-5.
  7. Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009;68(12):1870-. CrossRef
  8. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144(12):865-6. CrossRef
  9. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008;67(8):1096-03. CrossRef
  10. Kremer JM, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Westhovens R, et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis. 2011;70(10):1826-0. CrossRef
  11. Schiff M, Pritchard C, Huffstutter JE, Rodriguez-Valverde V, Durez P, Zhou X, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis. 2009;68(11):1708-4. CrossRef
  12. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353(11):1114-3. CrossRef
  13. Leffers HC, Ostergaard M, Glintborg B, Krogh NS, Foged H, Tarp U, et al. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis. 2011;70(7):1216-2. CrossRef
  14. Danoy P, Wei M, Johanna H, Jiang L, He D, Sun L, et al. Association of variants in MMEL1 and CTLA4 with rheumatoid arthritis in the Han Chinese population. Ann Rheum Dis. 2011;70(10):1793-. CrossRef
  15. Kojima T, Kaneko A, Hirano Y, Ishikawa H, Miyake H, Takagi H, et al. Early aggressive intervention with tocilizumab for rheumatoid arthritis increases remission rate defined using a Boolean approach in clinical practice. Mod Rheumatol. 2012;22:370-. CrossRef
  16. Kojima T, Kaneko A, Hirano Y, Ishikawa H, Miyake H, Oguchi T, et al. Study protocol of a multicenter registry of patients with rheumatoid arthritis starting biologic therapy in Japan: Tsurumai Biologics Communication Registry (TBCR) Study. Mod Rheumatol. 2012;22:339-5. CrossRef
  17. Yasuoka Y, Goto A, Seriu T, et al. Pharmacological properties and clinical efficacy of abatacept (Orencia^?) for the treatment of rheumatoid arthritis. Nihon Yakurigaku Zasshi. 2011;137(2):87-4. CrossRef
  18. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363(9410):675-1. CrossRef
  19. Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Nagaoka S, et al. Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study. J Rheumatol. 2011;38(8):1585-2. CrossRef
  20. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26-7. CrossRef
  21. Takeuchi T, Tanaka Y, Kaneko Y, Tanaka E, Hirata S, Kurasawa T, et al. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumatol. 2012;22:327-8. CrossRef
  22. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54(9):2817-9. CrossRef
  23. Takeuchi T, Tanaka Y, Amano K, Hoshi D, Nawata M, Nagasawa H, et al. Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients—REACTION?52-week study. Rheumatology (Oxford). 2011;50(10):1908-5. CrossRef
  24. Tanaka Y. Abatacept demonstrated long-term safety and efficacy in active RA patients who showed inadequate response to methotrexate: an analysis of the Japanese phase III open-label, long-term extension trial. Presented at the 14th Asian Pacific League of Associations for Rheumatology (APLAR) Congress. Hong Kong, 2010. p. FP6-1.
  
• 作者单位：Nobunori Takahashi (1)
  Toshihisa Kojima (1)
  Kenya Terabe (1)
  Atsushi Kaneko (2)
  Daihei Kida (2)
  Yuji Hirano (3)
  Takayoshi Fujibayashi (4)
  Yuichiro Yabe (5)
  Hideki Takagi (6)
  Takeshi Oguchi (7)
  Hiroyuki Miyake (8)
  Takefumi Kato (9)
  Naoki Fukaya (10)
  Hisato Ishikawa (2)
  Masatoshi Hayashi (11)
  Seiji Tsuboi (12)
  Daizo Kato (1)
  Koji Funahashi (1)
  Hiroyuki Matsubara (1)
  Yosuke Hattori (1)
  Masahiro Hanabayashi (1)
  Shinya Hirabara (1)
  Yutaka Yoshioka (1)
  Naoki Ishiguro (1)
  
  1. Department of Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan
  2. Department of Orthopedic Surgery and Rheumatology, Nagoya Medical Center, 4-1-1 Sanno-maru, Naka-ku, Nagoya, Aichi, Japan
  3. Department of Rheumatology, Toyohashi Municipal Hospital, 50 Hakken-nishi, Aotake-cho, Toyohashi, Japan
  4. Department of Orthopedic Surgery, Konan Kosei Hospital, 137 Oomatsubara, Takaya-cho, Konan, Aichi, Japan
  5. Department of Rheumatology, Tokyo Kosei Nenkin Hospital, 5-1 Tsukudo-cho, Shinjuku-ku, Tokyo, Japan
  6. Department of Orthopedic Surgery, Nagoya Kyoritsu Hospital, 1-172 Hokke, Nakagawa-ku, Nagoya, Japan
  7. Department of Orthopedic Surgery, Anjo Kosei Hospital, 28 Higashihirokute, Anjo, Japan
  8. Department of Orthopedic Surgery, Ichinomiya Municipal Hospital, 2-2-22 Bunkyo, Ichinomiya, Japan
  9. Kato Orthopedic Clinic, 8-4 Minami-myoudaiji-cho, Okazaki, Japan
  10. Department of Orthopedic Surgery, Kariya-Toyota General Hospital, 5-15 Sumiyoshi-cho, Kariya, Japan
  11. Department of Rheumatology, Nagano Red Cross Hospital, 5-22-1 Wakazato, Nagano, Japan
  12. Department of Orthopedic Surgery, Shizuoka Kosei Hospital, 23 Kitaban-cho, Aoi-ku, Shizuoka, Japan
  
• ISSN：1439-7609

文摘

Objectives The purpose of this study was to examine the treatment retention and efficacy of abatacept, the first member of a new class of biologic agents, in Japanese rheumatoid arthritis (RA) patients during clinical practice. Methods A retrospective multicenter study was conducted with patients who underwent abatacept therapy for 24?weeks (n?=?143). Results Patients at baseline had a mean age of 63.5?years, a mean disease duration of 11.3?years, and a mean disease activity score in 28 joints (DAS28) of 4.5. Overall retention of abatacept treatment was 83.2?% at 24?weeks, when 46.2?% of patients achieved DAS28-defined low disease activity (LDA; DAS28 <3.2) and 26.6?% achieved DAS28-defined remission (DAS28 <2.6). LDA was achieved in a significantly higher proportion of patients without prior biologics therapy compared to those with prior biologics (60.9 vs. 34.2?%, p?=?0.001). There was no significant difference between patients with or without concomitant methotrexate (MTX) therapy (45.2 vs. 47.5?%). Conclusions Abatacept therapy appears to be highly effective and well tolerated during clinical treatment of RA. Abatacept was particularly effective in patients with no history of biologics use, and did not appear to be dependent on concomitant MTX therapy.